Form 4: Wellington Biomedical Innovation Converts Preferred Stock to Common Stock in Boundless Bio IPO

Wellington Biomedical Innovation Master Investors converted Series B and C Preferred Stock into Common Stock upon the closing of Boundless Bio's initial public offering on April 2, 2024.

Summary

• On April 2, 2024, Wellington Biomedical Innovation Master Investors converted its Series B and Series C Preferred Stock into Common Stock of Boundless Bio, Inc. upon the closing of the company's initial public offering (IPO).
• The Series B Preferred Stock converted into 189,933 shares of Common Stock on a 19.5-for-1 basis.
• The Series C Preferred Stock converted into 366,300 shares of Common Stock on a 19.5-for-1 basis.
• Following the conversion, Wellington Biomedical Innovation Master Investors directly owns 556,233 shares of Boundless Bio Common Stock.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate action related to an IPO, indicating a positive step for the company. The conversion of preferred stock to common stock is generally viewed favorably as it simplifies the capital structure.

Positives

• The conversion of preferred stock to common stock simplifies Boundless Bio's capital structure following its IPO.
• Wellington Biomedical Innovation Master Investors maintains a significant equity stake in Boundless Bio, indicating continued investment.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This announcement is typical for companies completing an IPO, as preferred stock is often converted to common stock to simplify the capital structure and align shareholder interests.

Comparison to Industry Standards

• The conversion of preferred stock to common stock upon an IPO is a standard practice in the biotechnology industry.
• Similar conversions have been observed in recent biotech IPOs such as those of CG Oncology and ArriVent BioPharma, where preferred shares held by venture capital firms were converted to common stock at pre-determined ratios.

Stakeholder Impact

• Shareholders: The conversion simplifies the capital structure, potentially making the stock more attractive to a broader range of investors.
• Employees: The IPO and subsequent conversion can boost employee morale and align their interests with the company's success.

Key Dates